An observational study in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 10th largest by planned enrollment of the 19 observational ones that give a count, is one of 10 that started in 2026, is one of 19 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 37th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in Germany
Ages 18–130
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 2008; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 151 across 281 observational studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 109 across the 26 interventional studies, 500 across the 19 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
5 of the studies in Lupus Erythematosus, Systemic by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06530849Gracell Biotechnologies (Shanghai) Co., Ltd.A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | 2027-02-01 |
| NCT05141201AstraZenecaSAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.
The aim of this study is to describe congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other standard of care but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.
The population will encompass women with SLE of child-bearing potential age (15-49 years old) who start anifrolumab or other selected SLE treatments.
For the safety outcomes analyses the study population will include pregnant women and their infant born anytime during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria for EXPOSED SOURCE POPULATION:
- Pregnancies whose date of conception cannot be established
Inclusion criteria for UNEXPOSED SOURCE POPULATION:
Exclusion criteria for UNEXPOSED SOURCE POPULATION:
Inclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:
- Women with moderate/severe SLE
Exclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:
Pregnant individuals with a diagnosis of SLE who are exposed to anifrolumab at any time during pregnancy
Pregnant individuals with a diagnosis of moderate/severe SLE who are not exposed to anifrolumab at any time during pregnancy but who are exposed to other products for the treatment of SLE
Risk of major congenital malformations (MCM)
Describe and estimate the risk of MCM in live and non-live offspring from the women who had moderate/severe SLE and were exposed to anifrolumab during the first trimester of pregnancy or exposed to SOC and unexposed to anifrolumab during the first trimester of pregnancy
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Relative risk of MCM
Estimate the relative risk of MCM in live and non-live offspring from the women who had moderate/severe SLE and were exposed to anifrolumab during the first trimester of pregnancy or exposed to SOC and unexposed to anifrolumab during the first trimester of pregnancy
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Risk of select pregnancy loss outcomes
Describe and estimate the risk of select pregnancy loss outcomes (composite of spontaneous abortion and stillbirth) in all pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Relative risk of select pregnancy loss outcomes
Estimate the relative risk of select pregnancy loss outcomes (composite of spontaneous abortion and stillbirth) in pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Demographic and clinical characteristics
Describe the demographic and clinical characteristics of the live and non-live offspring and their mothers who had moderate/severe SLE and were exposed or unexposed to anifrolumab during the first trimester of pregnancy or anytime during pregnancy
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Risk of minor congenital malformations (mCM)
Describe and estimate the risk of mCM in live and non-live offspring from women with moderate/severe SLE who were exposed or unexposed to anifrolumab during pregnancy
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Relative risk of mCM
Estimate the relative risk of mCM in live and non-live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Risk of adverse pregnancy outcomes
Describe and estimate the risk of adverse pregnancy outcomes (ectopic pregnancy, spontaneous abortion, elective termination of pregnancy, stillbirth, infections requiring hospitalisation during pregnancy, emergency caesarean section) in all pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Relative risk of adverse pregnancy outcomes
Estimate the relative risk of adverse pregnancy outcomes (ectopic pregnancy, spontaneous abortion, elective termination of pregnancy, stillbirth, infections requiring hospitalisation during pregnancy, emergency caesarean section) in pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Risk of adverse birth outcomes
Describe and estimate the risk of adverse birth outcomes (preterm birth, small for gestational age (SGA)) in live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Relative risk of adverse birth outcomes
Estimate the relative risk of adverse birth outcomes (preterm birth, small for gestational age (SGA)) in live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy
Time frame: At delivery/birth
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2030, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →